摘要
目的探究弥漫大B细胞淋巴瘤(DLBCL)联合应用环磷酰胺+表柔比星+依托泊苷+长春新碱+泼尼松+利妥昔单抗(DA-EPOCH-R)方案与信迪利单抗的具体效果。方法选取2020年1月至2023年12月南阳市中心医院肿瘤内科收入诊治的82例DLBCL病例,以治疗方案的不同,将其分为研究组(n=41,信迪利单抗+DA-EPOCH-R方案),对照组(n=41,单纯应用DA-EPOCH-R方案),分析其疗效、血清标志物、免疫指标及并发症差异。结果研究组客观缓解率(ORR),疾病控制率(DCR)均高于对照组,差异均有统计学意义(P<0.05);治疗前,两组血清标志物、免疫指标比较,差异无统计学意义(P>0.05),治疗后,两组血清标志物、免疫指标指标均降低,且研究组低于对照组,差异均有统计学意义(P<0.05);治疗后,两组并发症发生率比较,差异无统计学意义(P>0.05)。结论DLBCL治疗期间,联合应用DA-EPOCH-R方案与信迪利单抗能够取得较为理想的临床疗效,改善血清标志物以及免疫指标,不会额外增加并发症发生率,具有临床应用意义。
Objective To explore the specific effects of combining cyclophosphamide,doxorubicin,etoposide,vincristine,prednisone,and rituximab(DA-EPOCH-R regimen)with sintilimab in the treatment of diffuse large B cell lymphoma(DLBCL).Methods A total of 82 DLBCL cases admitted and treated at the Oncology Department of Nanyang Central Hospital from January 2020 to December 2023 were selected.Based on different treatment regimens,they were divided into a study group(n=41,sintilimab+DA-EPOCH-R regimen)and a control group(n=41,DA-EPOCH-R regimen alone).The efficacy,serum markers,immune indicators,and complications were analyzed.Results The objective response rate(ORR)and disease control rate(DCR)in the study group were higher than those in the control group,with statistically significant differences(P<0.05).Before treatment,there were no statistically significant differences in serum markers and immune indicators between the two groups(P>0.05).After treatment,the serum markers and immune indicators in both groups decreased,and the levels in the study group were lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of complications between the two groups after treatment(P>0.05).Conclusion During the treatment of DLBCL,the combination of the DA-EPOCH-R regimen with sintilimab can achieve relatively ideal clinical efficacy,improve serum markers and immune indicators,and does not increase the incidence of complications,making it clinically significant.
作者
刘飒
LIU Sa(Third Ward of Oncology Department,Nanyang Central Hospital,Nanyang Henan 473000,China)
出处
《临床研究》
2024年第9期11-14,共4页
Clinical Research
